EN | 中文

BioNTech is Europes largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases, such as infectious diseases, allergies, and autoimmune disorders.

The Company has a variety of cutting-edge technologies, including mRNA Pharmaceuticals, cell & gene therapies, protein therapeutics and small molecules. Individualized specific immune-therapy using mRNA platform that aim to offer each patient a targeted therapy, which is highly effective and well-tolerated.

BioNTech develops a broad product pipeline using different scientific approaches and technology platforms, including oncology immunotherapy, infectious disease vaccines and protein replacement therapy.

BioNTech went IPO in October 2019, and its market cap has surpassed 80 billion USD in 2021.